CDEK
← All drugs Report issue

darotropium

Small moleculeexperimental

Clinical trial activity

11 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
5
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2005 (NCT00279019)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](CC(C#N)(c1ccccc1)c1ccccc1)C2.[Br-]
Mol. weight
425.41 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • darotropium
  • darotropium
  • darotropium bromide
  • darotropium bromide
  • gsk233705
  • gsk233705b
  • gsk233705b
  • gsk233705b

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00783003Phase 1Nov 1, 2008GlaxoSmithKline
NCT00749411Phase 2Nov 1, 2008GlaxoSmithKline
NCT00964405Phase 1Sep 1, 2008GlaxoSmithKline
NCT00671216Phase 1May 1, 2008GlaxoSmithKline
NCT00676052Phase 2May 1, 2008GlaxoSmithKline
NCT00500461Phase 1Jun 1, 2007GlaxoSmithKline
NCT00453687Phase 1Mar 1, 2007GlaxoSmithKline
NCT00453479Phase 2Mar 1, 2007GlaxoSmithKline
NCT00422604Phase 2Oct 1, 2006GlaxoSmithKline
NCT00376714Phase 2Aug 1, 2006GlaxoSmithKline
NCT00279019Phase 1Dec 1, 2005GlaxoSmithKline
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit111122005
1 organizations
Page 1 / 1